USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Bioluminescence Resonance Energy Transfer Assays for Clinical…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
84719
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
0711621
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Zymera Corporation
5941 OPTICAL COURT SAN JOSE, CA 95138-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: SBIR Phase I: Bioluminescence Resonance Energy Transfer Assays for Clinical Chemistry
Agency: NSF
Contract: 0711621
Award Amount: $99,993.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I research project aims to develop a point-of-care assay for creatine kinase, an important toxicity biomarker, to screen for adverse drug reactions (ADRs) using whole blood. The assay will utilize bioluminescent resonance energy transfer (BRET) probes incorporating quantum dots. The proposed technology is likely to impact toxicity testing, allowing physicians to test for potential ADR at an early stage and take corrective measures. With over 50% of Medicare patients taking multiple medications, the probability of ADRs is high and any inexpensive and reliable test for toxicity would be of benefit to these individuals and society as a whole.

Principal Investigator:

Daniel W. Sobek
DPhil
6505157897
daniel_sobek@zymera.com

Business Contact:

Daniel W. Sobek
DPhil
6505157897
daniel_sobek@zymera.com
Small Business Information at Submission:

Zymera Corporation
25 Bear Paw UAMS/BioVentures san jose, CA 95138

EIN/Tax ID: 721589494
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No